Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development-Reference-Cited by-同舟云学术

Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development

Published:2009-10-14 Issue:2 Volume:1 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Takala Shannon L.¹,Coulibaly Drissa²,Thera Mahamadou A.²,Batchelor Adrian H.³,Cummings Michael P.⁴,Escalante Ananias A.⁵,Ouattara Amed¹²,Traoré Karim²,Niangaly Amadou²,Djimdé Abdoulaye A.²,Doumbo Ogobara K.²,Plowe Christopher V.¹

Affiliation:

1. Howard Hughes Medical Institute and Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA.

2. Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Bamako, Bamako, Mali, West Africa.

3. University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.

4. Center for Bioinformatics and Computational Biology, University of Maryland, College Park, MD 20742, USA.

5. School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA.

Abstract

Children from Mali who are repeatedly infected with malaria are more likely to get sick if the parasite is highly variable, a possible obstacle to an effective vaccine.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference54 articles.

1. Genetic Polymorphism and Natural Selection in the Malaria Parasite Plasmodium falciparum

2. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’

3. M. Moran J. Guzman A. Ropars M. Jorgensen A. McDonald S. Potter H. Haile-Selassie The Malaria Product Pipeline: Planning for the Future (The George Institute of International Health London 2007); www.thegeorgeinstitute.org/shadomx/apps/fms/fmsdownload.cfm?file_uuid=1ABDE79C-DA73-20B3-D6E1-F7AF25011EC9&siteName=iih [accessed July 2009].

4. Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02

5. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5;Cell;2024-09

2. Genetic structure of apical membrane antigen-1 in Plasmodium falciparum isolates from Pakistan;Parasites, Hosts and Diseases;2024-08-26

3. Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex;Nature Communications;2024-06-07

4. Malaria vaccine development in Mali: a step towards transmission-blocking strategies;The Lancet Infectious Diseases;2024-04

5. Evaluating the genetic diversity of the Plasmodium vivax siap2 locus: A promising candidate for an effective malaria vaccine?;Acta Tropica;2024-03